Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage

• Published in: AIDS (London) Vol. 24; no. 8; pp. 1231 - 1233
• Main Authors: MORENO, Ana, QUEREDA, Carmen, FORTUN, Jesús, BARCENA, Rafael, PEREZ-ELIAS, María J, CASADO, José L, RODRIGUEZ-SAGRADO, Miguel A, MATEOS, María L, BLESA, Carlos, MORENO, Santiago
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 15.05.2010
• Subjects: Adult; AIDS/HIV; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - administration & dosage; Biological and medical sciences; Chemical and Drug Induced Liver Injury - drug therapy; Drug Therapy, Combination; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; HIV Infections - complications; HIV Infections - drug therapy; Human immunodeficiency virus 1; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - administration & dosage; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Polyethylene Glycols - administration & dosage; Recombinant Proteins; Ribavirin - administration & dosage; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral hepatitis; Antiretroviral agent; Mixed infection; Toxicity; Hepatic disease; Ribavirin; Integrase inhibitor; Nucleoside analog; Antiviral; Pegylated form; Viral hepatitis C; Human; Immunopathology; Drug combination; Cytokine; Retroviridae; AIDS; Immune deficiency; Lentivirus; Infection; Virus; Chemotherapy; Treatment; Viral disease; Digestive diseases; Interferon; Human immunodeficiency virus; Flaviviridae; Hepatitis C virus; Hepacivirus; Raltegravir
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/QAD.0b013e328336e9b3

Raltegravir (RAL), the first approved HIV-1 integrase-inhibitor, combines rapid and potent antiretroviral activity with a lack of interference with the hepatic cytochrome P450-3A4 [1,2], an advantage that makes it useful in certain settings, such as liver transplantation [3,4]. The low rate of hepatitis C virus (HCV) and/or hepatitis B virus-coinfected patients in pivotal trials of RAL [5,6] has precluded the availability of information on its potential use in patients with viral hepatitis-related liver damage, specially cirrhotic individuals. Moreover, to date, there are no data on the safety of RAL with pegylated-interferon (peg-IFN) and ribavirin (RBV). We report for the first time the safe co-administration of highly active antiretroviral therapy (HAART) including RAL with peg-IFN/RBV in five HIV individuals with HCV-related liver damage: low-grade fibrosis (n = 1), compensated cirrhosis (n = 1), decompensated cirrhosis (n = 2), and a severe form of HCV recurrence following liver transplantation (n = 1).